PARK7 and inflammatory bowel disease: In summary, although there are limitations of our study, including the number of the human samples, which do not let us to correlate the mucosal amount of PARK7 with disease activity index or other clinical parameters, we made great progress in the understanding of the biological effects of PARK7 in the pathomechanism of IBD.